术中^(125)Ⅰ粒子植入治疗晚期肺癌的临床意义  

Clinical value of ^(125)Ⅰ radioactive seeds implanting in treatment of advanced lung cancer

作　　者：韩振东[1] 张中太[1] 任杰远[2] 

机构地区：[1]齐齐哈尔医学院第三附属医院胸外科,黑龙江齐齐哈尔161041 [2]滨州市中心医院肿瘤科,山东滨州251700

出　　处：《肿瘤防治杂志》2005年第11期848-849,共2页China Journal of Cancer Prevention and Treatment

摘　　要：目的:探讨125Ⅰ放射性粒子治疗手术无法切除的晚期肺癌的临床意义。方法:采用开胸手术直视下肿瘤内粒子植入治疗晚期肺癌16例,观察患者术后生存率及症状缓解情况。结果:术后肺不张缓解率100.0%(16/16),疼痛缓解率87.5%(14/16),术后12、18和24个月生存率93.8%(15/16)、56.3%(9/16)和43.8%(7/16)。其他症状也明显缓解。结论:对于手术无法切除的晚期肺癌患者(主要为ⅢB患者),125Ⅰ放射性粒子术中植入近距离组织间照射治疗与传统放疗比较具有明显优势:精确的定位,可靠的疗效,最小的不良反应;是一种治疗晚期肺癌,延长患者生存时间,提高生存质量的新途径。OBJECTIVE:To explore the significance of implanting 125Ⅰ radioactive seeds into the tumor to treat advanced lung cancer that can not be removed by operation. METHODS: From January to October 2000,16 advanced lung cancer patients were treated with implanted seeds. RESULTS: After the operation, the remission rate of pulmonary atelectasis and pain was 100% and 87.5%; the 12-month, 18-month, over-24-month survival rates were 93.8%, 56.3%, 43.8% respectively; the other symptoms also remarkably improved. CONCLUSIONS: For advanced lung cancer (especially in Stage ⅢB), compared with radiotherapy, the interstitial brachy therapy with implanted 125Ⅰ radioactive seeds has many remarkable advantages: reliable response and minimal side effects. It is a new method to treat advanced lung cancer, to prolong the survival time and to improve the life quality.

关 键 词：碘放射性同位素 治疗应用 近距离放射疗法 肺肿瘤 随访研究 

分 类 号：R734.2[医药卫生—肿瘤]